Euronovis, in collaboration with Ixoreal Biomed—the producer of KSM-66® Ashwagandha, the world’s purest and most concentrated ashwagandha extract—is bringing one of the most extensively researched plants in natural medicine into a new era of pharmaceutical innovation.
The result? A groundbreaking pellet formulation, developed through extrusion-spheronization technology and designed to maximize both efficacy and ease of use.
What is Ashwagandha and why is it called “Indian ginseng”?
Scientifically known as Withania somnifera, ashwagandha is a perennial plant belonging to the Solanaceae family, native to India and used for more than 3,000 years in Ayurvedic medicine.
Considered a natural adaptogen, ashwagandha helps the body respond more effectively to physical and mental stress, improving emotional balance, concentration, energy levels, and sleep quality. Its active compounds, the withanolides, have antioxidant, anti-inflammatory, and neuroprotective effects similar to the ginsenosides found in Asian ginseng.
Scientifically proven benefits: less anxiety, more balance.
A recent meta-analysis conducted by the University of Modena and Reggio Emilia and published in 2025 in BJPsych Open has confirmed with clinical data what tradition has known for centuries.
By reviewing 14 clinical studies involving over 700 participants, researchers observed that the intake of Withania somnifera leads to a significant reduction in symptoms of anxiety, depression, and stress, and improves sleep quality—without relevant side effects.
The key findings highlighted include:
-
–1.62 standard deviations in anxiety symptoms compared to placebo
-
Improved mood and sleep quality
-
An excellent safety and tolerability profile, even after weeks of continuous use
- Reduction in serum cortisol levels
According to the authors, an average dose of 600 mg per day is effective for most individuals, confirming ashwagandha as one of the most promising adaptogens in the neuroscientific field.
The Euronovis revolution: Ashwagandha in pellet form
Leveraging its technological expertise in nutraceutical pelletization, Euronovis—together with Ixoreal Biomed—is developing a never-before-seen form of ashwagandha: pellets produced through extrusion and spheronization, designed to enhance the bioavailability and stability of the active ingredient.
The advantages of the new formulation include:
-
High active-ingredient concentration (75%)
-
Advanced pelletization technology for controlled release
-
Taste masking: a pleasant flavor with no bitter aftertaste
-
Simple and optimized intake
-
Greater uniformity and dosing precision
This innovation will make it possible to elevate the benefits of ashwagandha to a new level, combining natural tradition, exceptional raw-material quality, and precision pharmaceutical engineering.
From science to everyday life
The growing interest in ashwagandha is no coincidence. In an era unfortunately marked by chronic stress and anxiety-related disorders, this plant is emerging as a natural ally for both mental and physical well-being.
Scientific studies and clinical experience converge on one point: ashwagandha is a true stress regulator, capable of restoring balance and clarity.
With the new KSM-66® pellet formulation by Euronovis, ashwagandha will become even more effective, safe, and pleasant to take, opening new horizons for the premium nutraceutical supplements sector.
Contact us to learn more about this Euronovis innovation.
